Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
H10 PET-guided treatment adaptation trial in early-stage Hodgkin lymphoma
2005-002765-37Phase 3Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Jun 2006
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of doxorubicin, bleomycin, vinblastine, dacarbazine, etoposide and 4 more in Hodgkin lymphoma (HL) (3 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Progression-free survival. Started Jun 2006; status: completed.
02
Drugs
doxorubicinbleomycinvinblastinedacarbazineetoposide
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on 2005-002765-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002765-37.